Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Research in Mayo Clinic's Molecular Neurotherapeutics Laboratory, led by Tsuneya Ikezu, M.D., Ph.D., focuses on neuroimmune cell-mediated regulations of neuronal function, neurogenesis, neuroinflammation and neurodegeneration. Researchers in Dr. Ikezu's lab are particularly interested in how the innate immune-related cells, extracellular vehicles (EVs) and molecules in the central nervous system (CNS) influence the pathology and progression of select neurodegenerative disorders such as Alzheimer's disease (AD) and frontotemporal dementia.
Seminal work on the effect of CSF1R inhibitor on AD progression conducted by the Molecular Neurotherapeutics Lab stimulated the development and clinical trials of new CSF1R inhibitor on AD patients. In addition, Dr. Ikezu's invention on the cloning and functional characterization of TTBK1 leads this molecule as a new target of drug development for AD and related tauopathy.
Learn about clinical trials that address specific scientific questions about human health and disease.
Explore all research studies at Mayo Clinic.
See the peer-reviewed findings I have published as a result of my research.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.